Primary cutaneous peripheral T-cell lymphoma not otherwise specifiedNews & Research

4 curated articles for Primary cutaneous peripheral T-cell lymphoma not otherwise specified — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.

ℹ
UniteRare data is compiled from authoritative primary sources (FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, NORD), then processed through automated and AI-assisted extraction pipelines.
Report missing data
  1. Acta dermato-venereologica Apr 23, 2026

    Severe Ulceronecrotic Evolution during Mogamulizumab Treatment in a Patient with Primary Cutaneous Peripheral T-cell Lymphoma.

    Severe Ulceronecrotic Evolution during Mogamulizumab Treatment in a Patient with Primary Cutaneous Peripheral T-cell Lymphoma.

    Why it matters: Recent peer-reviewed research on Primary cutaneous peripheral T-cell lymphoma not otherwise specified that may be relevant for patients and caregivers.

  2. Journal of cutaneous pathology Apr 1, 2026

    Primary Cutaneous Peripheral T-Cell Lymphoma With TFH Phenotype With Divergent Clonal B- and Plasma-Cell Populations and DNMT3A Mutation.

    Primary cutaneous peripheral T-cell lymphoma with T-follicular helper phenotype (pcTFH-PTCL) is rare, and concurrent clonal B-lineage proliferations are uncommon. This lymphoma subtype presents unique diagnostic challenges due to its rarity and potential for misdiagnosis. We present a case of pcTFH-...

    Why it matters: Recent peer-reviewed research on Primary cutaneous peripheral T-cell lymphoma not otherwise specified that may be relevant for patients and caregivers.

  3. Clinical hematology international Mar 18, 2026

    Co-occurrence of angioimmunoblastic T-cell lymphoma and aggressive-refractory plasma-cell neoplasm: Two new cases and literature review.

    Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive peripheral T-cell lymphoma of T-follicular helper (TFH) cell origin, characterized by systemic manifestations, immune dysregulation, and frequent secondary B-cell proliferations. While Epstein-Barr virus (EBV)-related diffuse large B...

    Why it matters: Recent peer-reviewed research on Primary cutaneous peripheral T-cell lymphoma not otherwise specified that may be relevant for patients and caregivers.

  4. Cancers Feb 27, 2026

    At the Crossroads of Lineage: Secondary Malignancies After CAR-Based Immunotherapy.

    CD19-directed chimeric antigen receptor (CAR) T-cell therapies have been instrumental in improving outcomes of refractory or relapsed B-cell malignancies. However, there have been safety concerns due to recent reports of second primary malignancies (SPMs) related to CAR T-cell therapies. We reviewed...

    Why it matters: Recent peer-reviewed research on Primary cutaneous peripheral T-cell lymphoma not otherwise specified that may be relevant for patients and caregivers.

More on Primary cutaneous peripheral T-cell lymphoma not otherwise specified

Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.